الفهرس 
Introduction and Aim of WorkOnly 14 pages are availabe for public view
 |  | from | 174 |  |  |
| | | from | 174 | | |
Abstract
A number of prognostic factors has been identified in AML or CML or both, for example age, total leukocytic count, serum LDH, surface markers and cytogenetics.The aim of this work was to evaluate the clinical relevance of blood angiogenin levels in the sera of patients with myeloid leukemias. This study was carried out on 77 subjects divided as follow:- 37 patients with acute myeloid leukemia,25 patients with chronic myeloid leukemia and15 apparently healthy subjects as control group. The cases were subjected to the following:- Detailed history taking with thorough clinical examination. Routine laboratory investigations including: 1-complete blood count,Liver and kidney function tests. 2-ESR ,LDH, Bone marrow examination and immunophenotyping. Our results revealed the following :- 1-AML and CML cases showed high ESR – LDH and angiogenin levels when compared to the control group,after chemotherapy, AML patients achieved complete remission (CR) showed marked reduction in ESR, LDH and Angiogenin levels. 2-No significant difference in Angiogenin level in AML patients who achieved CR before chemotherapy when compared to non CR patients. 3-No significant correlation between serum Angiogenin levels and overall survival in AML and CML (blastic crisis group) patients. Conclusion:- Human Angiogenin is a powerful inducer of angiogenesis and potent diagnostic marker in myeloid malignancies, however its unreliable prognostic marker for monitoring the response to the therapy and duration of survival.